Latest news
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 7, 2026 - BioSpaceBioSpace · Mon, 10 Aug 2026 02:16:42 GMTOpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis - BioSpaceBioSpace · Wed, 29 Jul 2026 07:00:00 GMTIncyte cuts early-stage cancer drug to focus on next-gen programs - BioSpaceBioSpace · Wed, 29 Jul 2026 07:00:00 GMT